Canonical and non-canonical pathways of osteoclast formation

被引:2
作者
Knowles, H. J. [1 ]
Athanasou, N. A. [1 ]
机构
[1] Univ Oxford, Nuffield Orthopaed Ctr, Dept Pathol, Oxford OX3 7LD, England
关键词
Osteoclast; M-CSF; RANKL; resorption; osteolysis; COLONY-STIMULATING FACTOR; ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; GIANT-CELL TUMORS; OSTEOLYTIC BONE METASTASIS; HYPOXIA-INDUCIBLE FACTOR; FACTOR RECEPTOR GENE; OSTEOPROTEGERIN LIGAND; M-CSF; PHOSPHATIDYLINOSITOL; 3-KINASE;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Physiological and pathological bone resorption is mediated by osteoclasts, multinucleated cells which are formed by the fusion of monocyte / macrophage precursors. The canonical pathway of osteoclast formation requires the presence of the receptor activator for NFkB ligand (RANKL) and macrophage colony stimulating factor (M-CSF). Noncanonical pathways of osteoclast formation have been described in which cytokines / growth factors can substitute for RANKL or M-CSF to induce osteoclast formation. Substitutes for RANKL include LIGHT, TNF alpha and interleukins 6, 11 and 8. M-CSF substitutes include vascular endothelial growth factor (VEGF), placental growth factor (PlGF), FLt-3 ligand and hepatocyte growth factor (HGF). These growth factors can also influence canonical (RANKL / M-CSF-induced) osteoclast formation. Both canonical and noncanonical pathways of osteoclast formation play a role in the formation of osteolytic lesions where there is increased osteoclast formation and activity, such as in giant cell tumour of bone.
引用
收藏
页码:337 / 346
页数:10
相关论文
共 124 条
[31]  
2-A
[32]   ROLE OF COLONY-STIMULATING FACTOR-I IN BONE METABOLISM [J].
FELIX, R ;
HOFSTETTER, W ;
WETTERWALD, A ;
CECCHINI, MG ;
FLEISCH, H .
JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, 55 (03) :340-349
[33]   MACROPHAGE COLONY STIMULATING FACTOR RESTORES INVIVO BONE-RESORPTION IN THE OP/OP OSTEOPETROTIC MOUSE [J].
FELIX, R ;
CECCHINI, MG ;
FLEISCH, H .
ENDOCRINOLOGY, 1990, 127 (05) :2592-2594
[34]  
Ferracini R, 2000, J CELL PHYSIOL, V184, P191, DOI 10.1002/1097-4652(200008)184:2<191::AID-JCP6>3.0.CO
[35]  
2-B
[36]  
Flanagan A M, 1998, Curr Opin Hematol, V5, P181, DOI 10.1097/00062752-199805000-00006
[37]   Fra-1 replaces c-Fos-dependent functions in mice [J].
Fleischmann, A ;
Hafezi, F ;
Elliott, C ;
Remé, CE ;
Rüther, U ;
Wagner, EF .
GENES & DEVELOPMENT, 2000, 14 (21) :2695-2700
[38]   TGF-β isoform and receptor expression in giant cell tumor and giant cell lesions of bone [J].
Franchi, A ;
Benvenuti, S ;
Masi, L ;
Malentacchi, C ;
Arganini, L ;
Brandi, ML ;
Santucci, M .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2001, 9 (02) :170-175
[39]   The human osteoclast precursor circulates in the monocyte fraction [J].
Fujikawa, Y ;
Quinn, JMW ;
Sabokbar, A ;
McGee, JO ;
Athanasou, NA .
ENDOCRINOLOGY, 1996, 137 (09) :4058-4060
[40]   The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1,-3,-6, and-11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells [J].
Fujikawa, Y ;
Sabokbar, A ;
Neale, SD ;
Itonaga, I ;
Torisu, T ;
Athanasou, NA .
BONE, 2001, 28 (03) :261-267